醛固酮受体拮抗剂在心力衰竭合并肾功能不全患者中的应用
该研究汇总RALES与EMPHASIS-HF试验的个体患者数据,分析醛固酮受体拮抗剂(MRA)在射血分数降低的心力衰竭(HFrEF)患者中的疗效与安全性,重点关注随机化后eGFR降至<30 mL/min/1.73 m²的患者。结果显示,尽管这类患者基线心肾功能更差且主要结局风险更高,但MRA治疗带来的主要结局相对风险降低与未发生eGFR下降者相似,且绝对风险降低幅度更大,而严重高钾血症的绝对风险增加较小,提示eGFR下降至<30不应自动成为停用MRA的理由。
要点
- eGFR降至<30 mL/min/1.73 m²的HFrEF患者主要结局风险显著升高(HR 2.49)。
- MRA治疗在该人群中的相对风险降低与无eGFR下降者相似(HR 0.65 vs 0.63)。
- 该人群MRA治疗的绝对获益较大,严重高钾血症风险增加有限。
核心结论
- eGFR下降至<30 mL/min/1.73 m²不应自动导致停用MRA治疗。
- 在该高危人群中,MRA治疗的绝对风险降低幅度大。
研究设计与样本
- 汇总RALES和EMPHASIS-HF两项随机对照试验的个体患者数据,共纳入4355例患者。
- 根据随机化后eGFR是否降至<30 mL/min/1.73 m²进行分层分析。
主要发现
- 295例(6.8%)患者随机化后eGFR降至<30 mL/min/1.73 m²。
- 这些患者基线eGFR为47.3 ± 13.4 mL/min/1.73 m²,而无下降者为70.5 ± 21.8 mL/min/1.73 m²。
- eGFR下降至<30 mL/min/1.73 m²的患者主要结局风险更高(HR 2.49;95% CI 2.01-3.08;P < 0.001)。
- MRA治疗的主要结局风险降低在eGFR下降至<30 mL/min/1.73 m²者中(HR 0.65;95% CI 0.43-0.99)与未下降者中(HR 0.63;95% CI 0.56-0.71)相似(Pinteraction = 0.87)。
- 在eGFR下降至<30 mL/min/1.73 m²的患者中,MRA治疗每100人年减少21例主要结局事件,而严重高钾血症(>6.0 mmol/L)增加3例。
临床怎么用
- 对于HFrEF患者,即使eGFR降至<30 mL/min/1.73 m²,也应考虑继续MRA治疗而非自动停药。
- 需密切监测血钾,平衡获益与高钾血症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Kidney dysfunction often leads to reluctance to start or continue life-saving heart failure (HF) therapy. OBJECTIVES: This study sought to examine the efficacy and safety of mineralocorticoid receptor antagonists (MRAs) in patients with HF with reduced ejection fraction experiencing significant kidney dysfunction. METHODS: We pooled individual patient data from the RALES (Randomized Aldactone Evaluation Study) and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trials. The association between MRA treatment and outcomes was assessed according to whether the estimated glomerular filtration rate (eGFR) declined to <30 mL/min/1.73 m2 or not. The primary outcome was cardiovascular death or HF hospitalization. RESULTS: Among 4,355 patients included, 295 (6.8%) experienced a deterioration of eGFR after randomization to <30 mL/min/1.73 m2. These patients had more impaired baseline cardiac and kidney function (eGFR 47.3 ± 13.4 mL/min/1.73 m2 vs 70.5 ± 21.8 mL/min/1.73 m2) and had a higher risk of the primary outcome than patients without eGFR deterioration (HR: 2.49; 95% CI: 2.01-3.08; P < 0.001). However, the risk reduction in the primary outcome with MRA therapy was similar in those who experienced a decrease in eGFR to <30 mL/min/1.73 m2 (HR: 0.65; 95% CI: 0.43-0.99) compared with those who did not (HR: 0.63; 95% CI: 0.56-0.71) (Pinteraction = 0.87). In patients with a decrease in eGFR to <30 mL/min/1.73 m2, 21 fewer individuals (per 100 person-years) experienced the primary outcome with MRA treatment, vs placebo, compared with an excess of 3 more patients with severe hyperkalemia (>6.0 mmol/L). CONCLUSIONS: Because patients experiencing a decrease in eGFR to <30 mL/min/1.73 m2 are at very high risk, the absolute risk reduction with an MRA in these patients is large and this decline in eGFR should not automatically lead to treatment discontinuation.
引用
- Matsumoto, Henderson, Shen, et al. Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function. J Am Coll Cardiol. 2024. PMID: 38739064. doi:10.1016/j.jacc.2024.03.426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。